|
GB0614586D0
|
|
Pharmaceutical Formulation
|
|
US2006183696A1
|
|
Use of immune cell specific conjugates for treatment of inflammatory diseases of gastrointestinal tract
|
|
GB0602632D0
|
|
Preparation Of A Solid Dosage From Comprising Tacrolimus And/Or Sirolimus
|
|
CN101043907A
|
|
Use of immune cell specific conjugates for treatment of inflammatory diseases of gastrointestinal tract
|
|
US2006035845A1
|
|
Use of immune cell specific conjugates for treatment of inflammatory diseases of the gastrointestinal tract
|
|
WO2005100302A1
|
|
Solid state forms of (-)-(1r,2s)-2-amino-4-methylene-cyclopentanecarboxylic acid
|
|
IL165656D0
|
|
Novel nonsteroidal anti-inflammatory substances compositions and methods for their use
|
|
US2005130956A1
|
|
1-oxa 3-aza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the production thereof
|
|
WO2005035542A1
|
|
Solid-state form of alendronate sodium and preparation thereof
|
|
US2005131056A1
|
|
2- thia-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof
|
|
ZA200406971B
|
|
9-dexo-9a-aza-9a-methyl-9a-homoerythromycin a derivatives.
|
|
US2005004172A1
|
|
Solid state forms of 5-(difluoro-methoxy)-2-((3,4-dimethoxy-2-pyridinyl)-methyl) sulfinyl]-1H-benzimidazole sodium aquo complexes
|
|
WO2004106353A1
|
|
Process for selective alkylation of macrolide and azalide derivatives
|
|
WO2005021567A1
|
|
O-alkyl macrolide and azalide derivatives and regioselective process for their preparation
|
|
BR0312634A
|
|
New compounds, compositions and methods for treating inflammatory diseases and conditions
|
|
AU2003264917A8
|
|
Hybrid molecules of macrolides with steroid/non-steroid anti-inflammatory, antineoplastic and antiviral active molecules
|
|
BR0312584A
|
|
New non-steroidal anti-inflammatory substances, compounds and methods for their use
|
